Patient Perspectives from the Phase 3 IRAKLIA Study of Isatuximab (Isa) Subcutaneous (SC) via On-Body Injector (OBI) vs Isa Intravenous (IV) in Relapsed/Refractory Multiple Myeloma (RRMM)

Article2025

Isatuximab Subcutaneous (Isa SC) via On-Body Injector (OBI) or Manual Injection for Relapsed/Refractory Multiple Myeloma (RRMM): Patient Experience from the Phase 2 IZALCO Study

Gurdeep Parmar, Vânia Hungria, Meletios A Dimopoulos, Sosana Delimpasi, Fernanda Salles Seguro, Roman Hájek, Luděk Pour, Ivan Špıčka, Jiří Minařík, Marcelo Capra, Junichiro Yuda, Kazutaka Sunami, Herlander Marques, Graça Esteves, Christine Soufflet, Disa Yu, Erin Comerford, Florence Suzan, Paúl Cordero, Rick Zhang, Hang Quach

Article2025

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

Sikander Ailawadhi, Ivan Špıčka, Andrew Spencer, Jin Lu, Albert Oriol, Silvia Ling, Fredrik Schjesvold, Alejandro Berkovits, Marek Hus, Chunrui Li, Meletios A Dimopoulos, Péter Rajnics, Sevgi Kalayoğlu Beşışık, Vânia Hungria, Maria Del Rosario Custidiano, Gurdeep Parmar, Xavier Leleu, Fei Li, Claudio Cerchione, César Cinesi Gómez, Tadao Ishida,

Corrigendum2025

Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

Sikander Ailawadhi, Ivan Špıčka, Andrew Spencer, Jin Lu, Albert Oriol, Silvia Ling, Fredrik Schjesvold, Alejandro Berkovits, Marek Hus, Chunrui Li, Meletios A Dimopoulos, Péter Rajnics, Sevgi Kalayoğlu Beşışık, Vânia Hungria, Maria Del Rosario Custidiano, Gurdeep Parmar, Xavier Leleu, Fei Li, Claudio Cerchione, César Cinesi Gómez, Tadao Ishida,

Article2025

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

Jin Lu, Albert Oriol, Alejandro Berkovits, Andrew Spencer, César Cinesi Gómez, Chunrui Li, Claudio Cerchione, Fei Li, Fredrik Schjesvold, Gurdeep Parmar, Ivan Špıčka, Marek Hus, Maria Del Rosario Custidiano, Meletios A Dimopoulos, Péter Rajnics, Sevgi Kalayoğlu Beşışık, Sikander Ailawadhi, Silvia Ling, Vânia Hungria, Xavier Leleu, Florence Suzan Teisserenc,

Article2025

Efficacy and safety of isatuximab subcutaneous (SC) plus carfilzomib and dexamethasone (Isa-Kd) in patients with relapsed/refractory multiple myeloma (RRMM): Results of the phase 2 study IZALCO.

Gurdeep Parmar, Marcelo Capra, Fernanda Salles Seguro, Vânia Hungria, Meletios A Dimopoulos, Sosana Delimpasi, Jiří Minařík, Luděk Pour, Graça Esteves, Kazutaka Sunami, Junichiro Yuda, Ivan Spicka, Roman Hájek, Christine Soufflet, Disa Yu, Vera Hermina Kalika Koch, Florence Suzan, Hang Quach

Discussion(0)

Related publications

Isatuximab Subcutaneous (Isa SC) via On-Body Injector (OBI) or Manual Injection for Relapsed/Refractory Multiple Myeloma (RRMM): Patient Experience from the Phase 2 IZALCO Study

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

Efficacy and safety of isatuximab subcutaneous (SC) plus carfilzomib and dexamethasone (Isa-Kd) in patients with relapsed/refractory multiple myeloma (RRMM): Results of the phase 2 study IZALCO.